Vandortuzumab vedotin: Difference between revisions

Latest revision as of 11:15, 15 February 2025

Overview[edit]

Vandortuzumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It combines a monoclonal antibody specific to a target antigen on cancer cells with a potent cytotoxic agent, monomethyl auristatin E (MMAE), linked via a protease-cleavable linker. This allows for targeted delivery of the cytotoxic agent to cancer cells, minimizing damage to normal tissues.

Mechanism of Action[edit]

Vandortuzumab vedotin targets the CD70 antigen, which is overexpressed in various malignancies, including certain types of lymphoma and renal cell carcinoma. Upon binding to CD70, the ADC is internalized by the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the microtubule network, leading to cell cycle arrest and apoptosis.

Development and Clinical Trials[edit]

Vandortuzumab vedotin has been evaluated in several clinical trials to assess its safety and efficacy. Early-phase trials have shown promising results in terms of tumor response rates and manageable toxicity profiles. Ongoing studies aim to further define its role in the treatment of CD70-positive malignancies.

Side Effects[edit]

Common side effects of vandortuzumab vedotin include peripheral neuropathy, fatigue, nausea, and myelosuppression. These side effects are consistent with those observed with other vedotin-based ADCs, due to the action of MMAE on dividing cells.

Related pages[edit]

@@ Line 1: / Line 1: @@
-== Vandortuzumab Vedotin (RG7450): A Potential Therapeutic Agent for Cancer ==
+{{DISPLAYTITLE:Vandortuzumab vedotin}}
-'''Vandortuzumab Vedotin (RG7450)''' is a humanized [[monoclonal antibody]] that was specifically engineered with the intention of treating various forms of cancer. Created through biotechnological advancements, its development underscores the growing interest and investment in targeted therapies within the oncology field.
+==Overview==
+[[File:Vedotin_ADCs.svg|thumb|right|Diagram of vedotin antibody-drug conjugates]]
+'''Vandortuzumab vedotin''' is an [[antibody-drug conjugate]] (ADC) designed for the treatment of certain types of [[cancer]]. It combines a monoclonal [[antibody]] specific to a target antigen on cancer cells with a potent cytotoxic agent, [[monomethyl auristatin E]] (MMAE), linked via a protease-cleavable linker. This allows for targeted delivery of the cytotoxic agent to cancer cells, minimizing damage to normal tissues.
-=== Background ===
+==Mechanism of Action==
+Vandortuzumab vedotin targets the [[CD70]] antigen, which is overexpressed in various malignancies, including certain types of [[lymphoma]] and [[renal cell carcinoma]]. Upon binding to CD70, the ADC is internalized by the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the [[microtubule]] network, leading to cell cycle arrest and apoptosis.
-* '''Classification''': Humanized monoclonal antibody.
+==Development and Clinical Trials==
-* '''Primary Objective''': Treatment of cancer.
+Vandortuzumab vedotin has been evaluated in several [[clinical trials]] to assess its safety and efficacy. Early-phase trials have shown promising results in terms of tumor response rates and manageable toxicity profiles. Ongoing studies aim to further define its role in the treatment of CD70-positive malignancies.
-=== Mechanism of Action ===
+==Side Effects==
+Common side effects of vandortuzumab vedotin include [[peripheral neuropathy]], fatigue, nausea, and [[myelosuppression]]. These side effects are consistent with those observed with other vedotin-based ADCs, due to the action of MMAE on dividing cells.
-Vandortuzumab Vedotin, like other antibody-drug conjugates, is designed to selectively target cancer cells. It combines the specific targeting capabilities of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. By honing in on cancer cells and delivering a potent drug payload, the compound seeks to eliminate tumor cells while sparing healthy tissue, thereby reducing systemic side effects<ref>Jones RL, et al. Antibody-drug conjugates in solid tumors: a look into novel targets. Journal of Hematology & Oncology. 2021;14(1):1-14.</ref>.
+==Related pages==
+* [[Antibody-drug conjugate]]
+* [[Monomethyl auristatin E]]
+* [[CD70]]
+* [[Cancer treatment]]
-=== Developer Information ===
+[[Category:Antibody-drug conjugates]]
+[[Category:Cancer treatments]]
-* '''Company''': Vandortuzumab Vedotin was developed through a collaboration between [[Genentech]] and [[Roche]], two leaders in the biopharmaceutical industry.
-=== Clinical Development and Outcome ===
-* '''Research Phase''': Vandortuzumab Vedotin underwent various stages of clinical trials to assess its safety, efficacy, and potential therapeutic applications in oncology.
-* '''Discontinuation''': In 2017, the development of Vandortuzumab Vedotin was halted. The exact reasons for discontinuation often encompass a range of factors, from observed side effects to economic considerations or strategic focuses of the developing company<ref>Thomson Reuters. Discontinuation of clinical trials – reasons, challenges, and guidance. PLoS ONE. 2018;13(8):e020 in006.</ref>.
-=== Implications ===
-The development and subsequent discontinuation of Vandortuzumab Vedotin emphasizes the complexities and challenges inherent in drug development. While many compounds enter clinical trials, a significantly smaller number achieve market approval. However, each attempt contributes to the broader understanding of disease mechanisms and therapeutic interventions, potentially paving the way for future innovations<ref>Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715.</ref>.
-== Conclusion ==
-Vandortuzumab Vedotin stands as a testament to the continuous efforts within the pharmaceutical industry to innovate and improve therapeutic options for patients with cancer. Although this specific compound did not progress to market, the knowledge gained from its development remains invaluable for future research endeavors.
-== References ==
-<references />
-{{monoclonals for tumors}}
-{{monoclonal-antibody-stub}}
-[[Category:Monoclonal antibodies]]
-[[Category:Abandoned drugs]]
-{{nt}}